Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Gritstone bio, Inc. (GRTS) Create: Alert

All | News | Filings
Date FiledTypeDescription
09/27/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Gritstone bio Awarded BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19 Valued at up to $433 Million"
08/15/2023 8-K Other Events  Interactive Data
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Gritstone bio Reports Second Quarter 2023 Financial Results and Provides Corporate Updates -- Enrollment completed in Phase 2 portion of Phase 2/3 study evaluating GRANITE in first-line metastatic microsatellite-stable colorectal cancer ; preliminary efficacy data expected in 1Q 2024 -- -- Gritstone partnering with Friends of Cancer Research on Friends’ ctDNA for Monitoring Treatment Response Project, a collaborative research initiative to inform use of ctDNA change as surrogate for survival benefit -- -- Publication in Nature Communications of interim CORAL-BOOST results highlights the potential of Gritstone’s self-amplifying mRNA candidates to serve as next-generation vaccine against SARS-CoV-2 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $122.3 million as ..."
05/24/2023 4 Economides Vassiliki (See Remarks) has filed a Form 4 on Gritstone bio, Inc.
Txns: Bought 12,000 shares @ $1.9024, valued at $22.8k
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates -- Robust enrollment in Phase 2 portion of randomized Phase 2/3 study of GRANITE to date; 71 of 80 patients enrolled as of May 10, 2023-- -- Gritstone prioritizing GRANITE; expanding Phase 2 from 80 to 100 patients, enrollment completion expected in 3Q2023, preliminary data on approximately 50 patients expected in 1Q2024 -- -- Cash, cash equivalents, marketable securities, and restricted cash of $153.2 million as of March 31, 2023 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, CALIF."
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/06/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "First Amendment to Loan and Security Agreement, by and among Gritstone bio Inc., as borrower, Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), Hercules Capital, Inc., Hercules Capital Funding Trust 2022-1, each as a Lender, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the several banks and other financial institutions or entities form time to time party to the Loan and Security Agreement",
"First Amendment to Loan and Security Agreement, by and among Gritstone bio Inc., as borrower, Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (successor by purchase to the Federal Deposit Insurance Corporation as Receiver for Silicon Valley Bridge Bank, N.A. (as successor to Silicon Valley Bank)), Hercules Capital, Inc., Hercules Capital Funding Trust 2022-1, each as a Lender, and Hercules Capital, Inc., in its capacity as administrative agent and collateral agent for itself and the several banks and other financial institutions or entities form time to time party to the Loan and Security Agreement"
03/09/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/09/2023 10-K Annual Report for the period ended December 31, 2022
03/09/2023 8-K Quarterly results
Docs: "Gritstone bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates -- Preliminary data from GRANITE Phase 2/3 study remain expected in 4Q 2023 -- -- Phase 1/2 efficacy signals from “off-the-shelf” vaccine program consistent with those from GRANITE; randomized study of SLATE in patients with newly-diagnosed metastatic cancer to initiate in 2H 2023 -- -- Clinical evidence building for differentiation of self-amplifying mRNA as a potential next-gen mRNA platform in infectious disease -- -- Cash, cash equivalents, marketable securities, and restricted cash of $185.2 million as of December 31, 2022 -- -- Gritstone to host conference call today at 4:30pm ET -- EMERYVILLE, CALIF."
02/14/2023 SC 13G/A Avidity Partners Management LP reports a 3.3% stake in Gritstone bio, Inc.
02/14/2023 SC 13G/A Frazier Life Sciences Public Fund, L.P. reports a 6.3% stake in Gritstone bio, Inc.
02/10/2023 SC 13G/A EcoR1 Capital, LLC reports a 0% stake in Gritstone bio, Inc.
02/09/2023 SC 13G/A Versant Venture Capital V, L.P. reports a 3.5% stake in Gritstone Oncology, Inc.
02/06/2023 4 Jooss Karin (See Remarks) has filed a Form 4 on Gritstone bio, Inc.
Txns: Granted 252,763 shares @ $0
02/06/2023 4 Jones Erin (See Remarks) has filed a Form 4 on Gritstone bio, Inc.
Txns: Granted 252,845 shares @ $0
02/06/2023 4 Hawryluk Matthew (See Remarks) has filed a Form 4 on Gritstone bio, Inc.
Txns: Granted 191,771 shares @ $0
02/06/2023 4 Economides Vassiliki (See Remarks) has filed a Form 4 on Gritstone bio, Inc.
Txns: Granted 179,058 shares @ $0
02/06/2023 4 Cho James (Chief Accounting Officer) has filed a Form 4 on Gritstone bio, Inc.
Txns: Granted 64,515 shares @ $0
02/06/2023 4 Allen Andrew R (President and CEO) has filed a Form 4 on Gritstone bio, Inc.
Txns: Granted 738,550 shares @ $0
02/03/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/09/2023 8-K Quarterly results
12/14/2022 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
12/02/2022 EFFECT Form EFFECT - Notice of Effectiveness:
11/22/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
11/08/2022 D Form D - Notice of Exempt Offering of Securities:
11/03/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/03/2022 8-K Quarterly results
10/31/2022 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
10/25/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy